Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425658 | 0.94 | KCNMA1 (0.40) | GSK3BCYP2D6CYP1A2MTOR | |
| SCHEMBL3402193 | 0.92 | GSK3B (0.42) | GSK3BCYP2D6CYP1A2MTOR | |
| SCHEMBL3399684 | 0.91 | CRBN (0.42) | GSK3BCYP2D6CYP1A2MTOR | |
| SCHEMBL3399343 | 0.91 | GSK3B (0.47) | GSK3BCYP2D6CYP1A2MTOR | |
| SCHEMBL2065400 | 0.90 | F10 (0.43) | GSK3BCYP2D6CYP1A2F10 | |
| SCHEMBL3402173 | 0.90 | GSK3B (0.45) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3398468 | 0.90 | MTOR (0.40) | GSK3BF10MTOR | |
| SCHEMBL2064592 | 0.89 | F10 (0.44) | GSK3BCYP2D6CYP1A2F10 | |
| SCHEMBL3400823 | 0.89 | HTR4 (0.42) | CYP2D6CYP1A2 | |
| SCHEMBL2065363 | 0.88 | F10 (0.43) | GSK3BCYP2D6CYP1A2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507470-B2 | Substituted arylamide oxazepinopyrimidone derivatives | SANOFI (FR) | 2013-08-13 | — | — | US | claimed |
| EP-2247599-B1 | SUBSTITUTED ARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | SANOFI SA (FR) | 2012-11-28 | — | — | EP | claimed |
| US-20110015177-A1 | SUBSTITUTED ARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-01-20 | — | — | US | claimed |
| EP-2247599-A1 | SUBSTITUTED ARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2010-11-10 | — | — | EP | claimed |
| WO-2009095788-A1 | SUBSTITUTED ARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | claimed |
| EP-2085399-A1 | substituted arylamide oxazepinopyrimidone derivatives | Sanofi-Aventis (FR) | 2009-08-05 | — | — | EP | claimed |
| US-8507470-B2 | Substituted arylamide oxazepinopyrimidone derivatives | SANOFI (FR) | 2013-08-13 | — | — | US | disclosed |
| EP-2247599-B1 | SUBSTITUTED ARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | SANOFI SA (FR) | 2012-11-28 | — | — | EP | disclosed |
| US-20110015177-A1 | SUBSTITUTED ARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-01-20 | — | — | US | disclosed |
| EP-2247599-A1 | SUBSTITUTED ARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009095788-A1 | SUBSTITUTED ARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | disclosed |
| EP-2085399-A1 | substituted arylamide oxazepinopyrimidone derivatives | Sanofi-Aventis (FR) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015177-A1 | SUBSTITUTED ARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES | WEE1, NHERF1, WEE2 | GSK3B 748/4885CYP2D6 55/4885CYP1A2 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.